- Home
- STEX vs TIL Comparison
STEX vs TIL Comparison
Compare STEX & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEX | TIL |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.1M | 177.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | STEX | TIL |
|---|---|---|
| Price | $4.32 | $10.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $100.67 |
| AVG Volume (30 Days) | ★ 620.4K | 72.7K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $10.70 |
| 52 Week High | $14.11 | $42.79 |
Technical Indicators
Market Signals| Indicator | STEX | TIL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 36.08 |
| Support Level | N/A | $10.76 |
| Resistance Level | N/A | $11.51 |
| Average True Range (ATR) | 0.00 | 0.73 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 0.00 | 2.71 |
Price Performance
Historical ComparisonAbout STEX Streamex Corp.
Streamex Corp is a Real World Asset (RWA) tokenization company with Institutional grade infrastructure to bring the gold and commodities market on chain. Enabled by a gold denominated treasury and tokenization technology powering the modern commodities market.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.